Drugmaker Cipla has clocked a net profit of ₹555 crore for the fourth quarter ended March 31, 2026, down 55 per cent from ₹1,222 crore in the same period last year. The company’s total income from operations stood at ₹6,541 crore for the period under review, down 2.8 per cent from ₹6,730 crore in the same period, last year.
Achin Gupta, Cipla’s Managing Director and Global Chief Executive Officer, said, “In FY26, we recorded our highest-ever yearly revenue of INR 28,163 crore, reflecting the strength of our core businesses despite certain markets facing near-term challenges. Our One-India business surpassed the INR 12,500 crore annual revenue milestone. Key therapies in branded prescription business delivered robust double-digit growth, trade generics business sustained the strong growth momentum and anchor brands of consumer health business maintained leadership position.”
Giving an overview of the business, he said, “The US business posted an annual revenue of $780 million, supported by demand in our differentiated portfolio and a steady base business. In One Africa, we recorded a healthy annual growth of 7 per cent YoY in USD terms, driven by firm performance across key markets. Emerging Markets and Europe crossed the $400 million annualised revenue threshold on the back of deep market focus strategy.”
The focus will be on growing key markets, building on flagship brands, investing in future pipeline products and focusing on resolutions on the regulatory front, he added.
Cipla’s net cash position stood at INR 10,526 crore, and its debt primarily included lease liabilities working capital requirements, it said.
Published on May 13, 2026
